Mississauga, Ontario — MedX Health Corp. announced the commercial launch of SkinSecure, a cloud-based platform that connects the company’s SIAscope multispectral imaging devices with contract research organization and clinical trial sponsor workflows.
The software-as-a-service platform measures collagen, melanin, dermal melanin and hemoglobin in living skin through a siMedX Health Launches SkinSecure Platform for Noninvasive Skin Researchngle noninvasive scan that takes about 30 seconds. MedX said the system provides researchers with immediate access to objective biological data across multiple study sites and subjects.
SkinSecure is built on MedX’s patented SIAscopy technology, which also powers the company’s FDA-approved DermSecure platform. The company said the system can provide an alternative to invasive punch biopsies for clinical studies that use collagen measurements as an endpoint.
“Medicine established objective ways to measure our major systems long ago – the ECG for the heart, the EEG for the brain, the blood panel for what flows between them,” said John Gevisser, Chief Executive Officer of MedX Health. “Each became a standard. But what about skin, the body’s largest organ? We come at this challenge from first principles, and this gives us the method and the science to establish a new standard. It also enables us to track genuine biological change precisely over time and, uniquely, to measure collagen in absolute rather than relative or derivative terms.”
MedX is initially targeting dermatology trials, aesthetic biostimulator studies, topical skincare evaluations and medical spa research. The company said the platform could also support pharmaceutical development, regenerative medicine, oncology, wound healing, injectable biologics, nutraceutical studies and energy-based medical device research.
Clinical studies have traditionally relied on punch biopsies or indirect measurements to assess collagen. MedX said SkinSecure could reduce the cost, logistical burden and patient discomfort associated with biopsy-based studies while making repeated measurements easier.
“Every CRO running a direct collagen endpoint study today has had limited choice in terms of a measure – an invasive, expensive punch biopsy that by nature precludes longitudinal research, with subsequent expert histological analysis,” said John Gevisser, CEO at MedX Health. “With SkinSecure™, there is now a new choice – immediately-available quantitative data, obtained non-invasively. With around 1,000 active collagen trials running worldwide right now, this is not a niche problem; it is the defining measurement gap in this vertical of skin research. SkinSecure™ fills this gap, with instant cost and time savings from the first timepoint – a solution the industry has never had.”
The platform also offers cosmetics companies and consumer researchers an objective biological measurement tool for evaluating product performance. MedX said SkinSecure can simultaneously measure collagen production, vascular response and changes in skin pigmentation, allowing researchers to assess several endpoints with one scan.
The underlying SIAscopy technology has previously been used by more than 29 research organizations and sponsors to evaluate product efficacy. SkinSecure makes the technology available through a shared cloud-based service.
“For much of my career, I have advocated for the importance of direct measurement of skin biology rather than its derivatives,” said Dr. Paul Matts, Strategic Advisor to MedX Health and internationally-recognized skin researcher. “SkinSecure™ represents an important step forward because it enables the direct, concurrent, non-invasive measurement of collagen, melanin and haemoglobin in real time, creating new opportunities for researchers, product developers and clinicians to evaluate biological change with greater confidence. As the industry continues to move toward evidence-based decision-making, direct, objective measurement in vivo will become increasingly essential.”
